Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4461541 | 0.93 | ACHE (0.46) | ACHECHRM4TP53TDP1HSD11B1 | |
| SCHEMBL12651092 | 0.86 | ACHE (0.51) | ACHECHRM4TP53TDP1HSD11B1 | |
| SCHEMBL4442206 | 0.84 | ACHE (0.50) | ACHECHRM4TP53TDP1HSD11B1 | |
| SCHEMBL2550326 | 0.82 | L3MBTL3 (0.46) | TP53TDP1KDM4EALDH1A1 | |
| SCHEMBL2748651 | 0.80 | KDM4E (0.53) | TDP1HSD11B1CHRM1KDM4EALDH1A1 | |
| SCHEMBL11919045 | 0.80 | KMT2A (0.56) | ACHECHRM4HSD11B1KMT2ASMN1; SMN2 | |
| SCHEMBL4474282 | 0.79 | SMN1; SMN2 (0.50) | HSD11B1SMN1; SMN2KDM4E | |
| SCHEMBL2856149 | 0.79 | L3MBTL3 (0.51) | ACHETP53TDP1ALDH1A1 | |
| SCHEMBL27819985 | 0.79 | L3MBTL3 (0.38) | ACHETP53TDP1KMT2ASMN1; SMN2 | |
| SCHEMBL11919057 | 0.79 | SMN1; SMN2 (0.46) | ACHECHRM4TDP1HSD11B1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160362394-A1 | CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES | ABBVIE DEUTSCHLAND (DE) | 2016-12-15 | — | — | US | disclosed |
| US-9422264-B2 | Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-08-23 | — | — | US | disclosed |
| US-9403796-B2 | Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-08-02 | — | — | US | disclosed |
| US-20150352110-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | ABBVIE DEUTSCHLAND (DE) | 2015-12-10 | — | — | US | disclosed |
| US-20150158845-A1 | 5-HALOGEN-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSIN-DEPENDENT DISEASES | ABBVIE DEUTSCHLAND (DE) | 2015-06-11 | — | — | US | disclosed |
| US-9023854-B2 | 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressin-dependent diseases | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-05-05 | — | — | US | disclosed |
| US-20140378471-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | ABBOTT GMBH & CO. KG (DE) | 2014-12-25 | — | — | US | disclosed |
| US-20140315914-A1 | CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-10-23 | — | — | US | disclosed |
| US-8859557-B2 | Substituted oxindole derivatives and their use as vasopressin receptor ligands | ABBOTT GMBH & CO. KG (DE) | 2014-10-14 | — | — | US | disclosed |
| US-20140275110-A1 | AMIDOMETHYL-SUBSTITUTED OXINDOLE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT ILLNESSES | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | US | disclosed |
| US-20110092516-A1 | 5-HALOGEN-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSIN-DEPENDENT DISEASES | ABBOTT GMBH & CO. KG | 2011-04-21 | — | — | US | disclosed |
| US-20110077253-A1 | AMIDOMETHYL-SUBSTITUTED OXINDOLE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT ILLNESSES | ABBOTT GMBH & CO. KG (DE) | 2011-03-31 | — | — | US | disclosed |
| US-20110065720-A1 | CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES | ABOTT GMBH & CO KG (DE) | 2011-03-17 | — | — | US | disclosed |
| EP-2231643-A1 | AMIDOMETHYL-SUBSTITUTED OXINDOLE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT ILLNESSES | Abbott GmbH & Co. KG (DE) | 2010-09-29 | — | — | EP | disclosed |
| EP-2231645-A2 | 5-HALOGEN-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSINE-DEPENDENT DISEASES | Abbott GmbH & Co. KG (DE) | 2010-09-29 | — | — | EP | disclosed |
| WO-2010009775-A1 | CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES | ABBOTT GMBH & CO. KG (DE) | 2010-01-28 | — | — | WO | disclosed |
| EP-2114923-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | Abbott GmbH & Co. KG (DE) | 2009-11-11 | — | — | EP | disclosed |
| WO-2009071687-A1 | AMIDOMETHYL-SUBSTITUTED OXINDOLE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT ILLNESSES | ABBOTT GMBH & CO. KG (DE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071689-A2 | 5-HALOGEN-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSINE-DEPENDENT DISEASES | ABBOTT GMBH & CO. KG (DE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2008080973-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | ABBOTT GMBH & CO. KG (DE) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378471-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | AVPR2, AVPR1B, AVPR1A | ACHE 3261/4885CHRM4 933/4885TP53 3710/4885 |
| US-20160362394-A1 | CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES | AVPR2, AVPR1B, AVPR1A | ACHE 747/4885CHRM4 360/4885TP53 3364/4885 |
| US-20150352110-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | AVPR2, AVPR1B, AVPR1A | ACHE 3261/4885CHRM4 933/4885TP53 3710/4885 |
| US-20140315914-A1 | CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES | AVPR2, AVPR1B, AVPR1A | ACHE 747/4885CHRM4 360/4885TP53 3364/4885 |
| US-20110092516-A1 | 5-HALOGEN-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSIN-DEPENDENT DISEASES | AVPR2, AVPR1B, AVPR1A | ACHE 3442/4885CHRM4 2009/4885TP53 3215/4885 |
| US-20110077253-A1 | AMIDOMETHYL-SUBSTITUTED OXINDOLE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT ILLNESSES | AVPR2, AVPR1B, AVPR1A | ACHE 1568/4885CHRM4 948/4885TP53 4444/4885 |
| US-20150158845-A1 | 5-HALOGEN-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR TREATING VASOPRESSIN-DEPENDENT DISEASES | AVPR2, AVPR1B, AVPR1A | ACHE 3442/4885CHRM4 2009/4885TP53 3215/4885 |
| US-20110065720-A1 | CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES | AVPR2, AVPR1B, AVPR1A | ACHE 747/4885CHRM4 360/4885TP53 3364/4885 |
| US-20140275110-A1 | AMIDOMETHYL-SUBSTITUTED OXINDOLE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT ILLNESSES | AVPR2, AVPR1B, AVPR1A | ACHE 1568/4885CHRM4 948/4885TP53 4444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.